Calithera Biosciences is a clinical-stage, precision oncology biopharma company developing targeted therapies for biomarker-specific patient populations. Calithera is advancing a robust pipeline of investigational small molecules that target genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options. The oral SYK inhibitor, mivavotinib, is being studied in R/R non-GCB DLBCL. Sapanisertib, an oral mTORC1/2 inhibitor, is being evaluated in R/R NRF2m sqNSCLC.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No